Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection

July 19, 2022

Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target

July 12, 2022

Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022

April 19, 2022

Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)

March 2022

Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection

January 2022

Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis

January 2022